Bronconex Acticap

Land: Neuseeland

Sprache: Englisch

Quelle: Medsafe (Medicines Safety Authority)

Wirkstoff:

Mometasone furoate 400ug (anhydrous)

Verfügbar ab:

Organon (New Zealand) Limited

INN (Internationale Bezeichnung):

Mometasone furoate 400 µg (anhydrous)

Dosierung:

400 mcg/dose

Darreichungsform:

Powder for inhalation

Zusammensetzung:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Einheiten im Paket:

Inhaler, metered, DPI, (sample), 14 dose units

Klasse:

Prescription

Verschreibungstyp:

Prescription

Hergestellt von:

MSD International GmbH (Singapore Branch)

Anwendungsgebiete:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Produktbesonderheiten:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Berechtigungsdatum:

2000-12-05